Intravenous and oral whole body ketone dosimetry, biodistribution, metabolite correction and kinetics studied by (R)-[1-11C]β-hydroxybutyrate ([11C]OHB) PET in healthy humans

[1]  K. Clarke,et al.  On the interdependence of ketone body oxidation, glycogen content, glycolysis and energy metabolism in the heart , 2023, The Journal of physiology.

[2]  B. Egan,et al.  Exogenous Ketone Supplements in Athletic Contexts: Past, Present, and Future , 2022, Sports medicine.

[3]  D. Clegg,et al.  Starvation Ketosis and the Kidney , 2021, American Journal of Nephrology.

[4]  G. Várady,et al.  Alterations in erythrocyte membrane transporter expression levels in type 2 diabetic patients , 2021, Scientific Reports.

[5]  J. Finn,et al.  Estimation of fractional myocardial blood volume and water exchange using ferumoxytol‐enhanced magnetic resonance imaging , 2020, Journal of magnetic resonance imaging : JMRI.

[6]  N. Møller,et al.  SGLT2 Inhibition Does Not Affect Myocardial Fatty Acid Oxidation or Uptake, but Reduces Myocardial Glucose Uptake and Blood Flow in Individuals With Type 2 Diabetes: A Randomized Double-Blind, Placebo-Controlled Crossover Trial , 2020, Diabetes.

[7]  A. Lammertsma,et al.  11C Dosimetry Scans Should Be Abandoned , 2020, The Journal of Nuclear Medicine.

[8]  J. Rabinowitz,et al.  Comprehensive quantification of fuel use by the failing and nonfailing human heart , 2020, Science.

[9]  S. Selvaraj,et al.  Implications of Altered Ketone Metabolism and Therapeutic Ketosis in Heart Failure , 2020, Circulation.

[10]  M. Morris,et al.  Monocarboxylate Transporters (SLC16): Function, Regulation, and Role in Health and Disease , 2020, Pharmacological Reviews.

[11]  E. Croteau,et al.  Metabolism of Exogenous D-Beta-Hydroxybutyrate, an Energy Substrate Avidly Consumed by the Heart and Kidney , 2020, Frontiers in Nutrition.

[12]  K. Clarke,et al.  Cardiac ketone body metabolism. , 2020, Biochimica et biophysica acta. Molecular basis of disease.

[13]  R. Pluta,et al.  Ketogenic Diet in Alzheimer’s Disease , 2019, International journal of molecular sciences.

[14]  K. Whittingstall,et al.  A ketogenic drink improves brain energy and some measures of cognition in mild cognitive impairment , 2019, Alzheimer's & Dementia.

[15]  H. Bøtker,et al.  Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients , 2019, Circulation.

[16]  F. Flachskampf,et al.  Automatic calculation of myocardial external efficiency using a single 11C-acetate PET scan , 2018, Journal of Nuclear Cardiology.

[17]  K. Whittingstall,et al.  Ketogenic Medium Chain Triglycerides Increase Brain Energy Metabolism in Alzheimer's Disease. , 2018, Journal of Alzheimer's disease : JAD.

[18]  Joel Aanerud,et al.  Regional cerebral effects of ketone body infusion with 3-hydroxybutyrate in humans: Reduced glucose uptake, unchanged oxygen consumption and increased blood flow by positron emission tomography. A randomized, controlled trial , 2018, PloS one.

[19]  Michael G Stabin,et al.  RADAR Dose Estimate Report: A Compendium of Radiopharmaceutical Dose Estimates Based on OLINDA/EXM Version 2.0 , 2018, The Journal of Nuclear Medicine.

[20]  E. Croteau,et al.  Inverse relationship between brain glucose and ketone metabolism in adults during short-term moderate dietary ketosis: A dual tracer quantitative positron emission tomography study , 2017, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[21]  B. Egan,et al.  Metabolism of ketone bodies during exercise and training: physiological basis for exogenous supplementation , 2017, The Journal of physiology.

[22]  F. Jornayvaz,et al.  Effects of Ketogenic Diets on Cardiovascular Risk Factors: Evidence from Animal and Human Studies , 2017, Nutrients.

[23]  H. Bøtker,et al.  Ketone Body Infusion With 3‐Hydroxybutyrate Reduces Myocardial Glucose Uptake and Increases Blood Flow in Humans: A Positron Emission Tomography Study , 2017, Journal of the American Heart Association.

[24]  P. Puchalska,et al.  Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics. , 2017, Cell metabolism.

[25]  E. Ferrannini,et al.  CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis , 2016, Diabetes Care.

[26]  M. Fischereder,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2016, The New England journal of medicine.

[27]  T. Fulop,et al.  Lower brain 18F-fluorodeoxyglucose uptake but normal 11C-acetoacetate metabolism in mild Alzheimer's disease dementia. , 2014, Journal of Alzheimer's disease : JAD.

[28]  E. Croteau,et al.  [(11)C]-Acetoacetate PET imaging: a potential early marker for cardiac heart failure. , 2014, Nuclear medicine and biology.

[29]  M. Feinglos,et al.  Two diets with different haemoglobin A1c and antiglycaemic medication effects despite similar weight loss in type 2 diabetes , 2014, Diabetes, obesity & metabolism.

[30]  Timothy R. Arnett,et al.  The Key Role of the Blood Supply to Bone , 2013, Bone Research.

[31]  R. Schugar,et al.  Ketone body metabolism and cardiovascular disease. , 2013, American journal of physiology. Heart and circulatory physiology.

[32]  P. Duyck,et al.  Tissue perfusion in pathologies of the pancreas: assessment using 128-slice computed tomography , 2012, Abdominal Imaging.

[33]  Mark Muzi,et al.  Imaging of Cyclosporine Inhibition of P-Glycoprotein Activity Using 11C-Verapamil in the Brain: Studies of Healthy Humans , 2009, Journal of Nuclear Medicine.

[34]  H. Taniguchi,et al.  Quantitative measurement of human tissue hepatic blood volume by C15O inhalation with positron-emission tomography. , 2008, Liver.

[35]  R. Lecomte,et al.  [11C] Acetoacetate Utilization by Breast and Prostate Tumors: a PET and Biodistribution Study in Mice , 2008, Molecular Imaging and Biology.

[36]  P. Schubiger,et al.  Automated no-carrier-added synthesis of [1-11C]-labeled D- and L-enantiomers of lactic acid. , 2006, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[37]  P. O’Connor.  RENAL OXYGEN DELIVERY: MATCHING DELIVERY TO METABOLIC DEMAND , 2006, Clinical and experimental pharmacology & physiology.

[38]  George F Cahill,et al.  Fuel metabolism in starvation. , 2006, Annual review of nutrition.

[39]  J. Valentin.  Basic anatomical and physiological data for use in radiological protection: reference values , 2002, Annals of the ICRP.

[40]  S. Stone-Elander,et al.  Effect of acute hyperketonemia on the cerebral uptake of ketone bodies in nondiabetic subjects and IDDM patients. , 2002, American journal of physiology. Endocrinology and metabolism.

[41]  Britton Chance,et al.  Ketone Bodies, Potential Therapeutic Uses , 2001, IUBMB life.

[42]  B. Saltin,et al.  Skeletal muscle blood flow in humans and its regulation during exercise. , 1998, Acta physiologica Scandinavica.

[43]  S. Stone-Elander,et al.  Use of R-beta-[1-11C]hydroxybutyrate in PET studies of regional cerebral uptake of ketone bodies in humans. , 1995, The American journal of physiology.

[44]  J. Valentin.  The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103. , 2007, Annals of the ICRP.

[45]  S. Stone-Elander,et al.  Synthesis of [1-11C]-beta-hydroxybutyric acid. , 1991, Acta radiologica. Supplementum.

[46]  Radiological Protection in Biomedical Research. A report of Committee 3 adopted by the International Commission on Radiological Protection. , 1991, Annals of the ICRP.

[47]  Icrp.  Recommendations of the International Commission on Radiological Protection, ICRP Publication 26 , 1977 .